title: The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.
abstract: The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P = 0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).
authors.affiliation: Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya liochola@kemri-wellcome.org.
authors.forename: Lynette Isabella
authors.initials: LI
authors.lastname: Ochola-Oyier
authors.affiliation: Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
authors.forename: John
authors.initials: J
authors.lastname: Okombo
authors.affiliation: Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
authors.forename: Leah
authors.initials: L
authors.lastname: Mwai
authors.affiliation: Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Kiara
authors.affiliation: Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
authors.forename: Lewa
authors.initials: L
authors.lastname: Pole
authors.affiliation: Department of Immunology & Infection, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
authors.forename: Kevin K A
authors.initials: KK
authors.lastname: Tetteh
authors.affiliation: King Fahd University of Petroleum and Minerals, Department of Biology, Dhahran, Saudi Arabia.
authors.forename: Alexis
authors.initials: A
authors.lastname: Nzila
authors.affiliation: Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
authors.forename: Kevin
authors.initials: K
authors.lastname: Marsh
mesh_terms: D000962:Antimalarials / Q000494:pharmacology; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000494:pharmacology; D003062:Codon / Q000235:genetics*; D004338:Drug Combinations; D004351:Drug Resistance / Q000235:genetics*; D004983:Ethanolamines / Q000494:pharmacology*; D005449:Fluorenes / Q000494:pharmacology*; D006801:Humans; D007630:Kenya; D000078102:Lumefantrine; D016778:Malaria, Falciparum / Q000188:drug therapy / Q000473:pathology; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D015800:Protozoan Proteins / Q000235:genetics*
chemical_list: D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D003062:Codon; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; D015800:Protozoan Proteins; C031327:artemisinin; D000078102:Lumefantrine